Do you consider discontinuing maintenance therapy in transplant-ineligible patients with Multiple Myeloma?

Other than in the setting of disease progression or significant treatment-related adverse event?

Answer from: Medical Oncologist at Academic Institution

In absence of side-effects or relapse/progression, I continue maintenance in a dose-attenuated fashion for TI-NDMM based on available evidence in literature. I do encourage patients with standard risk disease to participate in trials asking the MRD-driven duration of maintenance question.

Comments

Medical Oncologist at Moffitt Cancer Center
Completely agree with @Saad.

Please select the option that best describes you:

Do you consider discontinuing maintenance therapy in transplant-ineligible patients with Multiple Myeloma?

Related Questions